Healthcare resource utilization and costs of US patients with small cell lung cancer treated with second-line therapies: a retrospective real-world database study.

X Fan¹, A Nguyen¹, B Rengarajan¹, J Shear¹, K J Moore¹, T L Barnes², N M Engel-Nitz², M G Johnson², J T Yan¹, A K Ganti³

¹Jazz Pharmaceuticals plc, Dublin, Ireland.

²Optum, Eden Prairie, Minnesota, USA.

³VA Nebraska Western Iowa Health Care System, University of Nebraska Medical Center, Omaha, Nebraska, USA.

PubMed DOI

Abstract

AIMS: To examine all-cause and myelosuppressive event (MYSPE)-related healthcare resource utilization and costs among patients with small cell lung cancer (SCLC) in the United States treated with second-line therapies. MATERIALS AND METHODS: This retrospective cohort study of the Optum Market Clarity database included adult patients with SCLC who completed platinum-based first-line induction ther…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Mentioned Companies

Optum
affiliation

MeSH Terms

Humans0Retrospective Studies0Small Cell Lung Carcinoma*Lung Neoplasms*Female0United States0Aged0Male0Middle Aged0Carbolines0Antineoplastic Agents*Heterocyclic Compounds, 4 or More Rings0Patient Acceptance of Health Care*Topotecan0Health Resources*Insurance Claim Review0Databases, Factual0Antineoplastic Combined Chemotherapy Protocols0Health Expenditures0

Keywords

Healthcare resource utilizationI00I10healthcare costsimmune-oncology therapylurbinectedinmyelosuppressive eventssecond-linesmall cell lung cancer

Article Info

PMID: 42892618
DOI: 10.1080/13696998.2026.2738358

How to Cite

Fan X et al. Healthcare resource utilization and costs of US patients with small cell lung cancer treated with second-line therapies: a retrospective real-world database study. J Med Econ2026;29(1):2491-2507. doi:10.1080/13696998.2026.2738358

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.